Incyte (INCY) 10-K Summaries & Annual Filing History
Review Incyte Corporation (INCY) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Incyte Corporation reported financial results for its most recent fiscal year. The company's revenue, operating income, net income, and operating cash flow all showed strong performance.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$5.1B
Revenue reported for the fiscal year.
Operating income
$1.5B
Income from operations reported for the year.
Net income
$1.3B
Net income reported for the year.
Operating cash flow
$1.4B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $3.4B | +13.7% |
| Dec 31, 2023 | $3.7B | +8.9% |
| Dec 31, 2024 | $4.2B | +14.8% |
| Dec 31, 2025 | $5.1B | +21.2% |
Business overview
The company is a biopharmaceutical firm focused on discovering and developing proprietary therapeutics. Its business overview describes operations in oncology and other disease areas.
Financial performance
Revenue grew compared to the prior year, while operating income and net income were substantial. Operating cash flow also remained positive, reflecting the company's profitability.
Material risks
The filing discusses risk factors that could affect the company's business, including industry competition, regulatory developments, and reliance on key products. These risks are outlined in the risk factors section.
Liquidity and capital
The company's liquidity and capital resources discussion indicates that it has generated sufficient cash flow to support its operations and investments. No specific capital allocation plans were detailed in the supplied context.
What to watch
Readers should monitor the company's revenue growth trajectory in the next filing.